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Abstract
The mevalonate pathway in human is responsible for the synthesis of cholesterol and other important
biomolecules such as coenzyme Q, dolichols and isoprenoids. These molecules are required in the cell for
functions ranging from signaling to membrane integrity, protein prenylation and glycosylation, and energy
homeostasis. The pathway consists of a main trunk followed by sub-branches that synthesize the different
biomolecules. The majority of our knowledge about the mevalonate pathway is currently focused on the
cholesterol synthesis branch, which is the target of the cholesterol-lowering statins; less is known about the
function and regulation of the non-cholesterol-related branches. To study them, we need a biological system
where it is possible to specifically modulate these metabolic branches individually or in groups. The nematode
Caenorhabditis elegans (C. elegans) is a promising model to study these non-cholesterol branches since its
mevalonate pathway seems very well conserved with that in human except that it has no cholesterol synthesis
branch. The simple genetic makeup and tractability of C. elegans makes it relatively easy to identify and manipulate
key genetic components of the mevalonate pathway, and to evaluate the consequences of tampering with their
activity. This general experimental approach should lead to new insights into the physiological roles of the non-
cholesterol part of the mevalonate pathway. This review will focus on the current knowledge related to the
mevalonate pathway in C. elegans and its possible applications as a model organism to study the non-cholesterol
functions of this pathway.
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1. Introduction
The main trunk of the mevalonate pathway is conserved
throughout the animal kingdom. The mevalonate path-
way converts acetyl-CoA to farnesyl diphosphate, and
produces precursors for several metabolically important
molecules as well as physiologically important end-pro-
ducts, including: 1) isopentenyl adenosine (important for
t-RNA modification); 2) coenzyme Q (an antioxidant
also important in the electron transport chain in mito-
chondria); 3) farnesyl diphosphate and geranylgeranyl
diphosphate (lipid moieties that can be added to pro-
teins to promote membrane association); 4) dolichol and
dolichol-phosphate (important for protein glycosylation);
and 5) cholesterol (precursor for bile acids and steroid
hormones) [1]. Many enzymes catalyze the multistep
pathway and its various branches, and several therapeu-
tic inhibitors exist that target some of these enzymes,
including statins (inhibitors of HMG-CoA reductase
typically prescribed to lower blood cholesterol) and
bisphosphonates (inhibitors of farnesyl diphosphate
synthase typically prescribed to prevent bone resorp-
tion). These therapeutics have several unexplained or
undesired effects, and are also likely to find novel medi-
cal indications as their effects become better under-
stood. For example, it has been suggested that statins
could have anticancer properties [2], could be used to
combat multidrug resistance during chemotherapeutic
cancer treatments [3], be used to improve the success of
hematopoietic transplantations [4], and even delay the
progress of neurological disorders such as Alzheimer
disease [5].
This review will summarize what is known about
the mevalonate pathway in C. elegans,w i t ht h ea i m
that this model organism may emerge as a useful tool
to further our understanding of this pathway, and dis-
cover novel applications for its pharmacological mod-
ulation. An interesting feature of using C. elegans for
the study of the mevalonate pathways is that it lacks
the cholesterol-synthetic branch present in mammals,
instead relying on dietary sources of sterols. C.
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lesterol branches of the pathway, which are well con-
served. Our previous research has already shown that
inhibiting the mevalonate pathway using statins in C.
elegans results in embryonic lethality, larval arrest
and adult sterility, and also causes mislocalization of
proteins that require isoprenylation for their mem-
brane targeting [6]. These findings suggest that the
mevalonate pathway is necessary for worm survival,
and that its non-cholesterol functions are evolution-
ary conserved.
2. The mevalonate pathway in C. elegans
2.1. Main trunk
The main trunk of the mevalonate pathway (see Figure
1) consists of the steps through which acetyl-CoA is
gradually transformed into the 5-carbon molecule iso-
pentenyl-PP (IPP), then on to the 15-carbon molecule
farnesyl-PP (FPP). The enzymes involved in these steps
have been extensively reviewed; see for example Mizior-
ko’s recent survey [7].
It is clear from Table 1 that the mevalonate pathway
in C. elegans is essential in the laboratory: RNAi knock-
down of any one of the eight enzymes that belong to
the main trunk of the pathway cause embryonic lethality
(1-8 in Table 1). This is valuable information since it
indicates that the laboratory diet of E. coli strain OP50
does not provide sufficient amounts of any of the meta-
bolites ranging from acetoacetyl-CoA to FPP. Consis-
tently, inhibiting the mevalonate pathway at the rate
limiting step of HMG-CoA reductase (HMGR) using
statins also causes embryonic lethality, which can be res-
cued by providing mevalonate exogenously (indeed
essentially all effects of statins in C. elegans are pre-
vented by mevalonate, demonstrating the absence of off-
target effects) [6].
Unfortunately, besides whole-genome RNAi
approaches, most enzymes of the main trunk have not
been studied genetically: isopentyl diphosphate isomer-
ase is the only main trunk enzyme for which there is a
mutant, called idi-1. This mutant is likely a hypomorph
since its phenotype is milder than the embryonic lethal-
ity observed in RNAi-treated animals, and consists of
larval paralysis and lethality, and defect in engulfment of
apoptotic corpses [8].
While the enzymes in the main trunk of the pathway
are essential, the experimental evidence reviewed
below so far suggests that none of the sub-branches
are in themselves strictly essential for viability in the
laboratory; it is likely that essential functions within
these pathways are robust due to genetic redundancy.
For example, isoprenylation of proteins may be
Figure 1 Overview of the mevalonate pathway. Circles represent the enzymes listed in Table 1. Red: RNAi causes embryonic lethality; Orange:
RNAi causes severe phenotypes; Green: RNAi causes mild phenotypes; and Black: RNAi causes no phenotype. Biosynthetic products written in
green are also exogenously supplied by the E. coli diet.
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that may exhibit some promiscuity in their substrate
specificities. We now turn our attention to each of the
five biosynthetic pathways that branch off the main
trunk of the mevalonate pathway.
2.2. Isopentyl adenosine
Isopentenyl phosphate, of which the synthesis is cata-
lyzed by diphosphomevalonate decarboxylase, can be
added to adenosine, producing isopentenyl adenosine.
When present in tRNA, isopentenyl (i6A) derivatives are
Table 1 Enzymes of the mevalonate pathway and their mutant or RNAi phenotypes in C. elegans.
No Human Enzyme Name (ID) BLAST
p
value
C.
elegans
ORF
C. elegans gene Phenotype Ref.
1 Acetyl-CoA transferase 1
(ACAT1)
1e-115 T02G5.8 kat-1 Embryonic lethal (RNAi); Excess fat and premature aging
(mutants)
[31,33,45,46]
2 HMG-CoA synthase
(HMGCS1)
2e-88 F25B4.6 Embryonic lethal (RNAi) [31,33,47]
3 HMG-CoA reductase
(HMGCR)
1e-111 F08F8.2 Embryonic lethal (RNAi); embryonic lethality, unfolded
protein response activation, mislocalized prenylation
reporter (statin treatment)
[7,31-33]
4 Mevalonate kinase (MVK) 3e-51 Y42G9A.4 mvk-1 Embryonic lethal (RNAi) [31,32]
5 Phosphomevalonate kinase
(PMVK)
5e-33 F32D8.13 Embryonic lethal (RNAi) [32,33]
6 Mevalonate (diphospho)
decarboxylase (MVD)
2e-61 Y48B6A.13 Embryonic lethal (RNAi) [48]
7 Isopentenyl diphosphate
isomerase (IDI1)
7e-32 K06H7.9 idi-1 Embryonic lethal (RNAi); larval paralysis and lethality, defect
in engulfment of apoptotic corpses (mutant)
[8,33]
8 Farnesyl diphosphate
synthase (FDPS)
4e-52 R06C1.2 fdps-1 Embryonic lethal (RNAi) [33]
9 tRNA
isopentenyldiphosphate
transferase (TRIT1)
9e-49 ZC395.6 gro-1 Maternal sterility (RNAi); deregulated developmental,
behavioral, and reproductive rates, as well as increased life
span (mutant)
[11,33]
10 prenyl (decaprenyl)
diphosphate synthase,
subunit 1 (PDSS1 or COQ1)
2e-72 C24A11.9 coq-1 Slow growth, uncoordinated, extended life span (RNAi);
larval development arrest, slowed pharyngeal pumping,
eventual paralysis and cell death (mutant)
[18,19,32]
11 4-hydroxybenzoate
polyprenyltransferase (COQ2)
2e-83 F57B9.4 coq-2 Extended life span (RNAi); larval development arrest,
slowed pharyngeal pumping, eventual paralysis and cell
death (mutant)
[18,19]
12 Dehydrodolichyl
diphosphate synthase
(DHDDS)
7e-55 T01G1.4 No data
13 Polyprenol reductase or
steroid 5 alpha-reductase 3
(SRD5A3)
6e-14 B0024.13 No RNAi phenotype [31,33]
14 Farnesyltransferase, CAAX
box, subunit alpha (FNTA)
1e-55 R02D3.5 fnta-1 Protruding vulva, egg-laying abnormal (RNAi) [31,32]
15 Farnesyltransferase, subunit
beta (FNTB)
3e-90 F23B12.6 fntb-1 No phenotype (RNAi) [31,33]
16 All-trans-GGPP synthase or
geranylgeranyl diphosphate
synthase
1e-6/
5e-05
C24A11.9/
R06C1.2
coq-1 and fdps-1
are the closest
homologs
See coq-1 and fdps-1
17 Protein geranylgeranyl
transferase type-1 subunit
beta (PGGT1B)
3e-73 Y48E1B.3 Larval lethal, larval arrest, postembryonic development
abnormal (RNAi)
[31,33]
18 Rab
geranylgeranyltransferase
type 2 subunit alpha
(RABGGTA)
5e-55 M57.2 Larval lethal, larval arrest, slow growth and induction of
unfolding protein response (UPR)(RNAi)
[7,31,32]
19 Rab
geranylgeranyltransferase
type 2 subunit beta
(RABGGTB)
1e-110 B0280.1 ggtb-1 Abnormal early embryo, developmental delay (RNAi) [33]
20 Farnesyl-diphosphate
farnesyltransferase 1 (FDFT1)
none none N/A N/A
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with U [9]. Modified nucleotides in tRNAs play an
important role in stabilizing codon-anticodon interac-
tions during translation, which is necessary to prevent
shifts of the translational reading frame. For example,
the hypermodified nucleoside 2-methylthio-N6 isopente-
nyl adenosine at position 37 (ms2i6A37) in tRNA
Phe
GAA
stabilizes mRNA-tRNA interactions in all three tRNA
binding sites [9,10]. In C. elegans, gro-1 is the homolog
of the human gene tRNA isopentenyldiphosphate trans-
ferase (TRIT1). Mutations in this gene result in deregu-
lated developmental, behavioral and reproductive rates,
as well as increased life span [11]. One likely interpreta-
tion of these phenotypes is that reduced fidelity of trans-
lation causes inefficiency of several processes, resulting
in a variable slow down of cellular events, which may
contribute to the increased life span. This explanation is
supported by the observation that mutations in other
tRNA modifying enzymes also cause developmental
delays and decreased reproductive capacity, especially at
t h eh i g hg r o w t ht e m p e r a t u r eo f2 5 ° Cw h i c hs h o u l d
further weaken codon-anticodon interactions during
translation [12]. In summary, tRNA modification
appears to be an important but not strictly essential
process of which the main function is to improve the
fidelity of translation in cases where the codon-antico-
don interaction involves a U-A pairing.
2.3. Coenzyme Q
The enzyme trans-prenyl transferase converts FPP to
polyprenyl-PP and is the limiting step in the synthesis of
Coenzyme Q (CoQ), also known as ubiquinol. CoQ con-
sists of a modified benzoquinone ring that can be rever-
sibly reduced and oxidized, and a hydrophobic isoprenyl
tail that contains 6-10 isoprenyl units (Figure 2). The
isoprenyl tail length of CoQ is species-specific, being 10
(CoQ10) in humans, nine (CoQ9) in rodents and C. ele-
gans,a n de i g h t( C o Q 8 )i nE. coli. CoQ is an active
molecule that functions as an electron carrier in the
mitochondrial electron transport chain. Electron transfer
via CoQ involves the formation of semiubiquinone radi-
cals, which cause the generation of superoxide radicals
upon reaction with oxygen. In the reduced form,
CoQH2 functions as a lipid-soluble antioxidant, and
protects cells from lipid peroxidation. Thus, CoQ is also
important as a lipophilic regulator of oxidative stress
[1]. Inhibition of HMG-CoA reductase using statins in
human causes a measurable decrease in serum levels of
CoQ, which correlates with a decrease in cardiac func-
tion that can be reversed by providing CoQ as a dietary
supplement [13,14].
CoQ is essential for development and survival of C.
elegans since mutants unable to synthesize CoQ and
grown on a bacterial food source lacking CoQ arrest
during embryognesis or emerge from dauers as sterile
adults [15,16]. A role for CoQ in regulating the timing
of developmental events first became apparent when the
gene clk-1 was shown to encode the worm homolog of
COQ7, an enzyme important for the biosynthesis of
CoQ [17]. clk-1 mutants grown on OP50, which pro-
vides some amount of nutritional CoQ, have deregulated
developmental timing, resulting on average in a slower
development and increased longevity. Similarly, RNAi
knock-down of several enzymes involved in the synth-
esis of CoQ also cause extended life span in worms
[18,19]. It has since become apparent that inhibition of
mitochondrial respiration or ubiquinol production in C.
elegans causes increased expression of cell-protective
and metabolic genes as well as increased abundance of
mitochondrial DNA, resulting in a slowing down of
behavioral rates and extended lifespan [20]. These
changes in gene expression have been called the ‘’retro-
grade response’’ since they rely on a reversal in the nor-
mal direction of information flow between the
mitochondria and nucleus [21]. The retrograde response
may be a compensatory reaction to the normal decline
in mitochondrial function seen with age since it is typi-
cally observed in older cells [21].
Besides its effects on biological rates and longevity,
CoQ contributes to the robustness of specific develop-
mental processes [22]. For example, the hypodermis is
abnormal in coq-8 mutants, with evidence of extracellu-
lar matrix degeneration. The gonad also develops abnor-
mally, and germ line viability and embryonic
development exhibit failure rates with a penetrance
varying from 2 to 40%, which suggests that CoQ pro-
vides an ancillary rather than critical function.
Depressed levels of CoQ could result in limiting levels
of ATP and pyrimidines with consequences on several
processes [22].
2.4. Dolichols
The polyisoprenoid alcohols (dolichols and polyprenols)
are found in all living organism, from bacteria to mammals
[23]. In animal and yeast cells polyisoprenoids are derived
from the cytoplasmic mevalonate pathway [24,25], and
most polyisoprenoids in animals are dolichols: a group of
long-chain mostly unsaturated organic compounds that
are made up of varying numbers of isoprene units termi-
nating in an a-saturated isoprenoid group, containing an
alcohol functional group. The key enzymes of dolichol
synthesis are cis-prenyltransferases (CTPs), responsible for
the construction of the long hydrocarbon skeleton. CPTs
elongate a short precursor, FPP, by sequential addition of
the desired number of IPP molecules that results in forma-
tion of a stretch of cis units.
Dolichols, which may be thought of as extremely
hydrophobic superlipids, are postulated to be involved
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defense against adverse environmental conditions. Doli-
chols also play a role in protein N-glycosylation: the
assembly of N-linked oligosaccharides in eukaryotes is
initiated by the transfer of GlcNAc 1-P from UDP-
GlcNAc to a dolichol-phosphate (Dol-P; specifically
dolichyl-phosphate) forming GlcNAc-P-P-Dol (See Fig-
ure 3) [26]. Dol-P is itself produced by polyprenol
Figure 2 Overview of the coenzyme Q biosynthetic pathway. The key step in the pathway is the condensation reaction of the
polyisoprenoid side-chain from the mevalonate pathway with 4-hydroxybenzoate, which is the product of a separate multi-step pathway
starting from the precursors tyrosine or phenylalanine. Since these precursors are in excess compared to the polyisoprenoids, the rate of
ubiquinol synthesis is determined by the availability of the polyisoprenoid: the conversion of Farnesyl-PP to polyprenyl-pp that is catalyzed by
enzyme trans-prenyl transferase is the rate limiting step in the synthesis of ubiquinol. Ubiquinol consists of a modified benzoquinone ring
attached to hydrophobic isoprenyl tail that contains 6-10 isoprenyl units depending on species. Doted lines represent additional enzymatic steps
in the pathway.
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between the dolichol biosynthetic pathway and congeni-
tal disorders of glycosylation [27-30]. During N-glycosy-
lation, Dol-P functions as a membrane anchor for the
formation of the oligosaccharide Glc3-Man9-GlcNAc2
(where Glc is glucose, Man is mannose, and GlcNAc is
N-acetylglucosamine). This oligosaccharide is transferred
from the dolichol donor onto certain asparagine resi-
dues of newly formed polypeptide chains. Dolichols are
also involved in the transfer of monosaccharides to the
Figure 3 Structure of Dolichol and their function during protein N-glycosylation. (A) Structure of Dolichol, where n is dependent on
particular cis-prenyltransferase. Dolichol phosphate is an isoprenoid compound (90-100 carbons total) made from dolichol by phosphorylation.
Dolichol phosphate performs important functions in synthesis of N-linked glycoproteins, as illustrated in (B). Dolichol phosphate is the structure
upon which the complex oligosaccharide is made before transfer to the target protein. The addition of the first moiety, N-acetylglucosamine
from UDP-N-acetylglucosamine, can be blocked by the antibiotic, tunicamycin. After assembly of the oligosaccharide is complete, the
carbohydrate structure is transferred from dolichol phosphate to an asparagine residue of a target protein having the sequence Asn-x-Ser/Thr,
where × is any amino acid. As also shown in (B), Dolichol phosphate can also act as a carrier of sugars to oligosaccharide chain synthesis
assembly; such activated sugars include dolichol-P-mannose and dolichol-P-glucose.
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tion, dolichols can be adducted to proteins as a post-
translational modification where they act as cofactors
for protein glycosylation in eukaryotes specifically for
the biosynthesis of N- and O-glycoprotein and GPI-
anchor [23].
The importance of dolichol biosynthesis in C. elegans
is not very clear. There is no data available for muta-
tions or RNAi knock-down of dehydrodolichyl dipho-
sphate synthase, which converts FPP to polyprenyl-PP
a n di st h ef i r s ts t e po ft h ed o l i c h o lb i o s y n t h e s i sb r a n c h
that emerges from the main trunk of the mevalonate
pathway. RNAi knock-down of the next enzyme, poly-
prenol reductase, causes no detectable phenotype (Table
1). Does that mean that protein glycosylation is unim-
portant in C. elegans?N o .S o m e14 6 5N-glycosylated
sites on 829 unique proteins have been identified in a
proteomics approach [31]. Many of these N-glycosylated
p r o t e i n sa r ee s s e n t i a l( e . g .t h et y r o s i n ep r o t e i nk i n a s e
let-23) or would give visible phenotypes if inhibited (e.g.
cell guidance genes such as unc-5 and sax-7) ,a n di ti s
simply not realistic to imagine that N-glycosylations do
not contribute to important functions in any of these
proteins. Furthermore, RNAi against enzymes involved
in later N-glycosylation steps do cause severe pheno-
types. For example RNAi knockdown of the worm
homolog of the oligosaccharide transferase subunit
STT3B (corresponding to the C. elegans ORF T12A.2)
causes abnormal embryos, some of which grow into thin
or long adults [32-34]. It is possible that the results of
RNAi against the polyprenol reductase provide an
incomplete picture regarding the importance of protein
glycosylation in C. elegans because there are alternative
pathways for dolichols synthesis [27].
2.5. Isoprenylated proteins
FPP can be converted to geranylgeranyl diphosphate
(GGPP) by the enzyme trans-prenyl transferase. Many
proteins owe their membrane association to their conju-
gation with FPP or GGPP moieties at their carboxyl ter-
minus, a reaction catalyzed by dimeric farnesyl-protein
transferases (FT) and geranylgeranyl-protein transferases
(GGT1 and GGT2), respectively [35].
Isoprenylation of many polypeptides in C. elegans has
been documented chemically [36]. Furthermore, isopre-
nylation is essential in C. elegans: treatment with glio-
toxin, a prenylation inhibitor [37,38], causes lethality
within 20 hours [36]. Querying PRENbase, a database
for protein CaaX farnesylation, CaaX geranylgeranyla-
tion and Rab geranylgeranylation, for all known or likely
C. elegans proteins that are prenylated either by FT,
GGT1 or GGT2 produces a list of 49 C. elegans proteins
falling into 9 clusters (See Additional file 1, Table S1).
As expected, the three largest types of prenylated
proteins in C. elegans are small GTPases: rab-like (28
proteins), ras-like (9 proteins) and rho/rac-like (6 pro-
teins). The rab-like proteins are predicted to be mostly
geranylgeranylprenylated by GGT2, while the ras-like
and rho/rac-like may be prenylated by either GGT1 or
FT. Many of the rab-like proteins are essential for
embryogenesis and viability, four of the rho/rac-like pro-
teins are essential (CED-10, CDC-42, RHO-1 and RAC-
2) and only two of the ras-like proteins are essential
(LET-60 and RHEB-1). The fact that many small
GTPases implicated as oncogenes in human cancers are
dependent on farnesylation or geranylgeranylation for
their activity has led to the suggestion that statins could
be effective anticancer agents since inhibition of HMG-
CoA reductase would deplete the availability of the lipid
moieties [35,39]. Importantly, C. elegans is also a rele-
vant model in this context since statin treatment
resulted in loss of prenylation of a CaaX-tagged GFP
reporter, as well as causing growth arrest as previously
mentioned (6).
None of the RNAis against the alpha or beta subunits
of FT, GGT1 or GGT2 individually cause lethality
(Table 1), while RNAi against specific prenylated small
GTPases often does cause lethality (Additioanl file 1,
Table S1). This means either that prenylation of small
GTPases is not essential to their activities, or that the
prenyltransferases can act redundantly on important
substrates.
Besides the small GTPases, a small number of other
proteins may be prenylated by FT or GGT1 in C. ele-
gans (Additional file 1, Table S1), but this has not been
demonstrated experimentally except for the nuclear
lamin. Aging C. elegans exhibit characteristic changes in
nuclear morphomlogy that are dependent on prenylated
nuclear lamin, and prevented by the use of the prenyla-
tion inhibitors gliotoxin or manumycin [40].
2.6. Cholesterol
Cholesterol is an important component of many animal
membranes, where it has significant effects on mem-
brane properties, and is also a precursor to many steroid
derivatives, including several hormones. C. elegans is a
cholesterol auxotroph and it has no homologue for the
enzyme squalene synthase (also known as farnesyl-
diphosphate farnesyltransferase 1, or FDFT1). Therefore
C. elegans does not use the mevalonate pathway to
synthesize squalene or its derivative, cholesterol.
Although cholesterol is not synthesised by C. elegans,i t
is essential for its survival, and is required for various
biological processes, namely molting, reproduction,
dauer formation and metabolism [41-44]. In the wild, C.
elegans obtains cholesterol from its diet; in laboratory
conditions, worms obtain it from bacteria and from the
culture media, which is supplemented with cholesterol.
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from a cholesterol-fed mother grows and produces pro-
geny normally, whereas the following generation arrests
as L2 larvae [42,45]. These arrested larvae recover and
follow normal development when provided with the
final product of sterol the biosynthesis pathway, but not
if intermediates are supplied, again demonstrating that
C. elegans lack cholesterol synthesis machinery [46].
These findings also indicate that sterol is required in
minor amounts for worm survival, and that it is pro-
vided via oocytes to the progeny. The main sterol trans-
porting proteins in C. elegans are vitellogenins,
homologues of mammalian apolipoproteins; these pro-
teins are required for transporting sterols from the
intestine to the oocytes via RME-2, a vitellogenin recep-
tor [47,48]. The C. elegans sterol distribution has been
studied using dehydroergosterol (DHE), a fluorescent
analogue of cholesterol, which can functionally replace
it. DHE accumulates in only small subsets of cells,
namely nerve ring cells, pharynx cells, excretory gland
cells, intestinal cells, oocytes and spermatozoa
[45,49,50]. It is estimated that sterols in C. elegans lipid
extracts are 20 times less abundant than in mammalian
cells [51]. This reduced amount may be sufficient for
the cell membrane of these specialized cells, and it is
possible that the remaining cells do without cholesterol
in their membranes. Note however that caveolin-1, a
bona fide caveolae protein typically present in choles-
terol-rich micro domains in plasma membrane, is found
in C. elegans membrane extracts, indicating that lipid
rafts are formed in this organism [52].
The evidence that sterols in C. elegans are required as
precursors for hormones and other biologically active
compounds came from the fact that cholesterol-deprived
worms have molting defects and resemble dauer larvae,
a diapause stage adapted to harsh conditions. The verte-
brate gp330/megalin/LRP-2 protein homologue in
worms, lrp-1, is required for molting and likely func-
tions as a sterol receptor in hypodermal cells since
megalin is an LDL receptor-related protein required for
absorption of vitamin D [53].
Finally, work on two C. elegans genes, daf-9 and daf-
12, suggests that sterols are also involved in dauer for-
mation. daf-9 encodes a cytochrome P450 of the CYP2
subfamily that produces the dafachronic acid that pro-
motes dauer entry by inhibiting daf-12, a nuclear hor-
mone receptor [54-57]. Mutations in two other genes
also indicate a role for sterols in regulating dauer forma-
tion: the ncr-1 and ncr-2 (C. elegans Niemann-Pick C1
protein homologues 1 and 2) are predicted to be
involved in intracellular sterol trafficking, as with their
human homologues which are required for intracellular
cholesterol homeostasis [58]; ncr-1;ncr-2 double mutants
constitutively form dauers.
3. Regulation of the mevalonate pathway
In eukaryotes, the mevalonate pathway is regulated at
the transcriptional, translational and post-translational
levels [59]. In mammals and yeast, sterols are modulate
the function of various enzymes of the mevalonate path-
way, depending on their concentration in the cell. The
rate-limiting enzyme of the mevalonate pathway, HMG-
CoA reductase (HMGR), is tightly regulated to control
lipid homeostasis in the cell [60]. This regulation is
achieved by sterol-mediated feedback inhibition to
maintain appropriate levels of sterols and other branch-
specific end-products in the cell [59]. In cholesterol-
replete cells, the transcription factor SREBP (sterol regu-
latory element-binding protein) binds to the integral
membrane protein Scap (sterol regulatory element-bind-
ing protein cleavage-activating protein) in the ER and
becomes inactive. When cholesterol is depleted, this
complex is transported to the Golgi apparatus, where
SREBP undergoes proteolytic events resulting in its acti-
vation. The activated protein is transported to the
nucleus and activates HMGR transcription [61]. Another
important protein is Insig (insulin-induced gene), which
in cholesterol-replete cells targets HMGR for proteolytic
degradation, alone or with SREBP [62,63]. Insig-depen-
dent HMGR degradation is also mediated by isoprenoids
(geranylgeraniol; FPP) and these molecules also regulate
HMGR at the translational level, although the molecular
mechanisms behind this phenomenon are not clear
[59,64-67]. Besides HMGR, sterols also regulate the
expression of the HMG-CoA synthase and the LDL-
receptors at the transcriptional level to maintain their
optimal concentration in the cell.
The absence of the cholesterol synthetic branch in the
C. elegans mevalonate pathway opens the possibility that
the pathway in worms may be regulated differently than
in mammalian and yeast cells: one would expect the
products from the non-cholesterol branches to regulate
the pathway, rather than the levels of sterols. However,
this has not been addressed experimentally. It is how-
ever interesting to note that while C. elegans does con-
tain homologues of SREBP and SCAP, it lacks an Insig
gene [68]. The C. elegans SREBP homologue (sbp-1)i s
required for fat storage and regulates genes involved in
fatty acid synthesis similarly to [69,70], but it is not
known if it also regulates the mevalonate pathway.
4. Considerations regarding the Km for entry into
the different branches of the pathway
To determine the severity with which each branch of
the pathway would be affected if the common trunk
were inhibited, as would occur upon statin treatment, it
may be useful to know the Km of the enzymes involved.
While this has not been determined in C. elegans,s o m e
information exists for mammalian cells. The Kms, some
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T a b l e2 .G i v e nt h eK m so ft h ed ifferent steps, it seems
that as mevalonate becomes limiting in mammalian
cells, the branches to be affected would be first the
synthesis of cholesterol (via squalene), then the geranly-
geranylation of proteins, then the production of CoQ,
and finally and only when mevalonate becomes almost
completely depleted, the farnesylation of proteins. No
information on the Km involved in the conversion of
IPP to Dolichol-P could be found, and the Km of 0.4
μM for the CoQ branch is very much uncertain, as it is
based on a rough cell assay. If these Kms are roughly
preserved in C. elegans, one expects the bulk of the pro-
ducs of the mevalonate pathway to be utilized for the
production of geranylgeranyl-diphosphate and of CoQ.
5. Experimental approaches to delineate key
components and their biological roles
In mammals, the cholesterol synthesis sub-branch of the
mevalonate pathway has been the most intensely studied
due to the proposed involvement of cholesterol in ather-
osclerosis. Since this sub-branch is absent in C. elegans,
this organism may be eminently suitable to study the
non-cholesterol sub-branches of the pathway. Experi-
mentally, this problem can be tackled in several ways,
the most common being: 1) RNAi knock-down or muta-
tion of the genes encoding the enzymes of the pathway;
2) Use of inhibitors to specifically block the whole path-
way or individual sub-branches; and 3) Metabolic rescue
of the individual sub-branches in the context of animals
where the main trunk is inhibited.
In the first case, each enzyme of the pathway is
k n o c k e dd o w ni nt u r nb yf e e d i n gw i t hb a c t e r i ae x p r e s -
sing double stranded RNA (dsRNA) against them or by
isolating deletion mutants. RNAi can be done broadly,
for all the enzymes in the route, or specifically for the
rate-limiting enzymes such as the HMG CoA reductase
or trans-prenyl transferase. This method is especially
important to study genes in the mevalonate pathway
that are essential for survival or genes for which
mutants are not yet available. Previous studies have
shown that RNAi against enzymes in the main truck
leads to lethal phenotype in C. elegans but not RNAi
against enzymes of sub-branches (Table 1 and Figure 1).
This suggests that there is no single non-cholesterol
sub-branch that is essential for survival or that there is
genetic redundancy within one or more essential sub-
branch.
A second approach to probe the mevalonate pathway
is to block its main trunk or various sub-branches using
inhibitors of the specific enzymes. Such inhibitors
include statins that inhibit HMG CoA reductase,
bisphosphonates that inhibit farnesyl diphosphate
synthase, manumycin and gliotoxin that inhibit farnesyl-
transferase, and several others (Table 3). Treatment with
many of these inhibitors, specifically statins, bisphospho-
nates, manumycin and gliotoxin, have been tested in C.
elegans and were found to cause growth arrest and leth-
ality [6,37,40]. Farnesyltransferase inhibitors (FTIs) have
been shown to cause developmental defects and inhibi-
tion of protein prenylation in C. elegans. FTIs treatment
also suppresses age dependent nuclear morphology
defects and defects caused by an activated form of the
ras protein (let-60)i nC. elegans [37,40]. Similarly, we
have previously shown that statins can be used to inhibit
the mevalonate pathway in C. elegans, which not only
caused lethality, but also caused loss of protein prenyla-
tion and induced the Unfolded Protein Response (UPR);
these effects were rescued by providing downstream
metabolites of the mevalonate pathway indicating the
specific activity of the statins in C. elegans [6].
Mutagenesis screens for mutants that are resistant to
inhibitors that block main trunk of the pathway (statins
and bisphosphonates), or inhibit the sub-branches (man-
umycin; gliotoxin) are key to identify additional genes
that are dependent on, or regulators of, this pathway.
Genetic loci causing resistance can easily be identified in
C. elegans either by genetic mapping approach or by
whole genome sequencing. Once identified it is rela-
tively straightforward to perform functional and genetic
interaction studies in C. elegans because of its short life
cycle, well-studied morphology and simple genetic
makeup.
Another experimental approach is metabolic rescue of
the different branches of the pathway by selectively pro-
viding branch specific metabolites (such as Coenzyme
Q9; GGPP; FPP; IPP) to C. elegans where the main
mevalonate branch is inhibited either by inhibitors like
statins or by RNAi. This approach is not only helpful in
identifying the major non-cholesterol branch but also to
determine their phenotypic contribution.
Conclusions
C. elegans uses the mevalonate to synthesize metabolites
other than cholesterol that are important for various
biological processes, ranging from translation fidelity to
protein localization, protein N-glycosylation and energy
homeostasis. Inhibiting the synthesis of these metabo-
lites by blocking the key enzymes through specific
Table 2 Estimated Km values for limiting steps in the
mevalonate pathway.
Reaction Km Reference
FPP - > Squalene 2 μM [80]
FPP- > GGPP 1 μM [81]
FPP- > CoQ 0.4 μM [82]
FPP- > Protein Farnesylation 5 nM [83]
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embryonic lethality, demonstrating the importance of
these metabolites for survival. The ready ability to
manipulate different branches of the pathway in C. ele-
gans using RNAi or inhibitors makes it an excellent
model to study their biological roles and regulation.
Previous studies have already established that statins
can inhibit the mevalonate pathway in C. elegans as it
does in other eukaryotic organisms and this inhibition
results in mislocalization of intracellular signaling mole-
cules such as small GTPases (Rho, Ras, Rac and Rab)
[72,73]. These small GTPases are key biological switches
that regulate signaling in the cell and that require preny-
lation for their proper localization. Mutations in these
G T P a s ea r eo n eo ft h em a n yc a u s e so ft u m o rp r o g r e s -
sion and metastases [74], and identifying GTPases that
are regulated by the mevalonate pathway in C. elegans
can be a way to understand the role of the mevalonate
pathway in regulating the mammalian homologs, and
contribute to the effort to develop therapeutic
approaches to modulate their activity, especially in can-
cerous cells.
Numerous studies have shown that statins have
broader beneficial effects besides regulating cholesterol
levels; these include anticancer effects, suppressive effects
on the development of protein aggregates, and anti-
inflammatory effects [75-78]. However, little is known
about the underlying genetic basis of these non-choles-
terol effects. Therefore, identifying genes that are
involved in statin resistance in C. elegans may contribute
to our understanding of the non-cholesterol statin effects
in higher organisms. Such a research effort will also help
in recognizing genetic factors that are responsible for
poorly understood statin side effects, such as myopathy,
neuropathy and insomnia [79]. To summarize: studies of
the mevalonate pathway in C. elegans could be of great
aid in addressing important medical issues.
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